To hyperfractionate or not to hyperfractionate-Is it really a question?

0Citations
Citations of this article
5Readers
Mendeley users who have this article in their library.

Abstract

Despite technical advances the last decade, patients with HPV/p16 negative head and neck cancer (being smokers and having affected performance and co-morbidities), still have a poor outcome after treatment. Hyperfractionated radiotherapy with concurrent cisplatin might be a reasonable way to pursue for improving their outcome. This strategy requires that adequate supportive care is available.

Cite

CITATION STYLE

APA

Eriksen, J. G., & Merlano, M. C. (2016, June 1). To hyperfractionate or not to hyperfractionate-Is it really a question? European Oncology and Haematology. Touch Briefings. https://doi.org/10.17925/eoh.2016.12.01.19

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free